KMX names David McCreight interim CEO as Board trims to nine
Rhea-AI Filing Summary
CarMax (KMX) announced leadership changes. The Board terminated President and CEO William D. Nash effective December 1, 2025, under his severance agreement. He also resigned from the Board effective the same date, and the Board will be reduced to nine directors.
The Board appointed director David W. McCreight as Interim President and CEO effective December 1, 2025. In this role, he will receive a $1,200,000 annual base salary and RSUs with a grant-date fair value of $3,600,000 that vest on the first anniversary, with pro‑rata vesting based on months served as interim CEO. He will not receive separate director compensation while serving as interim CEO.
Effective December 1, 2025, Thomas J. Folliard will serve as Interim Executive Chair. Mr. McCreight will step down from the Compensation and Personnel Committee; Shira Goodman will join the Committee and Mark O’Neil will serve as chair. CarMax also furnished a press release announcing preliminary third-quarter expectations and these changes.
Positive
- None.
Negative
- None.
Insights
Leadership transition with interim appointments and defined pay.
CarMax named David W. McCreight Interim President and CEO effective December 1, 2025, following the Board’s termination of William D. Nash under his severance agreement and his concurrent Board resignation. The Board size will be nine directors after the change.
Compensation for the interim role is clearly specified: an annual base salary of $1,200,000 and RSUs with a grant-date fair value of $3,600,000, vesting on the first anniversary with pro‑rata vesting tied to months served. Thomas J. Folliard becomes Interim Executive Chair, reinforcing board-level oversight during the transition.
Committee adjustments place Mark O’Neil as chair of the Compensation and Personnel Committee and add Shira Goodman to the Committee on December 1, 2025. The company furnished a press release with preliminary Q3 expectations; actual impact depends on subsequent disclosures when results are reported.